LGD-3303
Muscle Growth & Body CompositionAlso known as: LGD3303, Ligand 3303
Mechanism
LGD-3303 is an orally active SARM developed by Ligand Pharmaceuticals with strong anabolic effects on both muscle and bone. Preclinical studies show it can increase bone mineral density and lean muscle mass while maintaining selectivity over reproductive tissues.
Technical detail
LGD-3303 is a non-steroidal, orally bioavailable SARM developed by Ligand Pharmaceuticals that acts as a full agonist at the AR in muscle and bone tissue. In ovariectomized rat models, it demonstrated potent increases in femoral bone mineral density and cortical bone mass comparable to DHT, with concurrent anabolic effects on muscle. It exhibits tissue selectivity through differential AR cofactor recruitment. It was not advanced into clinical trials and remains a preclinical research compound.